Marshall Wace, LLP Adaptive Biotechnologies Corp Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$6.26 - $9.34 $388,113 - $579,070	-61,999 Reduced 14.34%	370,471 $2.83 Million
Q3 2022 Nov 14, 2022	SELL	$6.5 - $12.67 $1.66 Million - $3.23 Million	-254,794 Reduced 37.07%	432,470 $3.08 Million
Q2 2022 Aug 15, 2022	SELL	$6.4 - $14.73 $1.52 Million - $3.51 Million	-238,254 Reduced 25.74%	687,264 $5.56 Million
Q1 2022 May 16, 2022	BUY	$10.12 - $28.9 $8.55 Million - $24.4 Million	845,225 Added 1052.68%	925,518 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$25.17 - $36.85 $2.02 Million - $2.96 Million	80,293 New	80,293 $2.25 Million
Q2 2021 Aug 13, 2021	SELL	$32.22 - $44.59 $5.49 Million - $7.6 Million	-170,442 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$37.26 - $67.74 $6.35 Million - $11.5 Million	170,442 New	170,442 $6.86 Million
Q4 2019 Feb 14, 2020	SELL	$24.56 - $32.8 $60,024 - $80,163	-2,444 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$30.31 - $53.51 $74,077 - $130,778	2,444 New	2,444 $76,000

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.